
InflaRx launches emergency Covid-19 treatment in the US
Biopharmaceutical company InflaRx has launched Gohibic (vilobelimab) in the US for the treatment of Covid-19. In April 2023, Gohibic was granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in hospitalised adults when initiated within 48 hours of… Read More
